Wedge Capital Management L L P NC Purchases 11,566 Shares of Prestige Consumer Healthcare Inc. $PBH

by · The Markets Daily

Wedge Capital Management L L P NC lifted its holdings in shares of Prestige Consumer Healthcare Inc. (NYSE:PBH – Free Report) by 29.8% in the third quarter, according to its most recent filing with the SEC. The firm owned 50,347 shares of the company’s stock after acquiring an additional 11,566 shares during the period. Wedge Capital Management L L P NC’s holdings in Prestige Consumer Healthcare were worth $3,142,000 as of its most recent filing with the SEC.

Several other hedge funds have also recently added to or reduced their stakes in PBH. Intech Investment Management LLC grew its position in Prestige Consumer Healthcare by 18.9% during the 1st quarter. Intech Investment Management LLC now owns 27,307 shares of the company’s stock worth $2,348,000 after acquiring an additional 4,343 shares during the last quarter. AXQ Capital LP acquired a new position in Prestige Consumer Healthcare in the second quarter worth $694,000. Voya Investment Management LLC grew its holdings in shares of Prestige Consumer Healthcare by 19.5% during the first quarter. Voya Investment Management LLC now owns 41,717 shares of the company’s stock worth $3,586,000 after purchasing an additional 6,798 shares during the last quarter. Keystone Wealth Services LLC bought a new stake in shares of Prestige Consumer Healthcare during the second quarter worth $315,000. Finally, Wealth Enhancement Advisory Services LLC raised its holdings in shares of Prestige Consumer Healthcare by 13.4% in the second quarter. Wealth Enhancement Advisory Services LLC now owns 9,571 shares of the company’s stock valued at $765,000 after buying an additional 1,134 shares during the last quarter. Institutional investors and hedge funds own 99.95% of the company’s stock.

Insiders Place Their Bets

In related news, VP Jeffrey Zerillo sold 719 shares of the business’s stock in a transaction that occurred on Friday, November 28th. The shares were sold at an average price of $60.00, for a total transaction of $43,140.00. Following the completion of the transaction, the vice president owned 42,329 shares in the company, valued at approximately $2,539,740. The trade was a 1.67% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 1.40% of the stock is owned by insiders.

Analysts Set New Price Targets

Several equities research analysts have weighed in on PBH shares. Weiss Ratings restated a “hold (c)” rating on shares of Prestige Consumer Healthcare in a research report on Wednesday, October 8th. Oppenheimer dropped their price objective on shares of Prestige Consumer Healthcare from $82.00 to $72.00 and set an “outperform” rating for the company in a research report on Tuesday, October 21st. Canaccord Genuity Group lowered their target price on Prestige Consumer Healthcare from $100.00 to $88.00 and set a “buy” rating for the company in a research note on Friday, November 7th. Zacks Research upgraded Prestige Consumer Healthcare from a “strong sell” rating to a “hold” rating in a report on Monday, November 10th. Finally, Jefferies Financial Group dropped their price objective on Prestige Consumer Healthcare from $75.00 to $71.00 and set a “hold” rating for the company in a report on Monday, October 27th. Four equities research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $85.33.

View Our Latest Stock Report on PBH

Prestige Consumer Healthcare Stock Up 1.5%

Shares of Prestige Consumer Healthcare stock opened at $62.65 on Tuesday. The business has a fifty day simple moving average of $60.73 and a 200 day simple moving average of $67.80. The stock has a market cap of $3.01 billion, a PE ratio of 15.55, a price-to-earnings-growth ratio of 1.94 and a beta of 0.39. The company has a quick ratio of 2.51, a current ratio of 3.70 and a debt-to-equity ratio of 0.55. Prestige Consumer Healthcare Inc. has a 12 month low of $57.25 and a 12 month high of $90.04.

Prestige Consumer Healthcare (NYSE:PBH – Get Free Report) last issued its earnings results on Thursday, November 6th. The company reported $1.07 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.97 by $0.10. The firm had revenue of $274.11 million for the quarter, compared to analysts’ expectations of $257.14 million. Prestige Consumer Healthcare had a return on equity of 12.43% and a net margin of 18.09%.The company’s revenue was down 3.4% compared to the same quarter last year. During the same quarter last year, the business earned $1.09 earnings per share. Prestige Consumer Healthcare has set its FY 2026 guidance at 4.540-4.580 EPS. Research analysts predict that Prestige Consumer Healthcare Inc. will post 4.5 EPS for the current year.

About Prestige Consumer Healthcare

(Free Report)

Prestige Consumer Healthcare, Inc is a leading manufacturer and marketer of branded over-the-counter (OTC) healthcare products. The company focuses on developing, acquiring and commercializing a diverse portfolio of non-prescription remedies designed to address common consumer health needs, including pain relief, cold and cough, digestive health, eye care, skin care and women’s health.

Key brands in Prestige’s portfolio include Clear Eyes (eye health), Carmex (lip care), Chloraseptic (sore throat relief), Dramamine (motion sickness), Rolaids (antacid), Monistat (women’s health), BC Powder (pain relief), Little Remedies (pediatric cold and gas relief) and TheraTears (dry eye therapy).

Further Reading

Want to see what other hedge funds are holding PBH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Prestige Consumer Healthcare Inc. (NYSE:PBH – Free Report).